JPRN-UMIN000015887已完成未知
Salvage TACE for unresectable HCC: switching the chemotherapeutic agents. - Switching chemotherapeutic agents in TACE
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)HCC with macrovascular invasion and/or extrahepatic metastasis 2)Child-Pugh score =/> 10 3)Patients who cannot be performed TACE technically 4)Patients received previous cisplatin-based chemotherapy 5)Patients received previous systemic chemotherapy
研究者
相似试验
已完成
4 期
Study to Collect more detailedinformation concerning TACE treatment followed by Sorafenib for hepatocellularcarcinoma (HCC) or without sorafenib after TACE enabling us to evaluate thetime to meet criteria for TACE non-eligibilityCTRI/2014/12/005310Bayer pharmaceuticals Pvt Ltd55
已完成
3 期
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCCHepatocellular CarcinomaNCT01229839Sun Yat-sen University668
Unknown
2 期
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular CarcinomaPHENYTOIN/SORAFENIB [VA Drug Interaction]Carcinoma, HepatocellularNCT01605734Shandong Cancer Hospital and Institute120
已完成
不适用
miriplatin-TAI in TACE refractory HCCTACE Refractory HCCJPRN-UMIN000005408ational Cancer Center Hospital40
撤回
不适用
Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular CarinomaHepatocellular CarcinomaNCT03079778Lawson Health Research Institute